EYP-1901 for Wet Age-Related Macular Degeneration

EYP-1901 for Wet Age-Related Macular Degeneration
56%45%34%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 45.0%
EyePoint Pharmaceuticals, Inc. ($EYPT)
No stock close$13.79$12.60$11.41May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • EYPT $11.70May 19 • EYPT $11.82May 20 • EYPT $12.50May 21 • EYPT $12.78May 22 • EYPT $12.93May 26 • EYPT $13.35May 27 • EYPT $13.16May 28 • EYPT $13.50

Will this trial show a positive result on Average change in best corrected visual acuity (BCVA), Weeks 52 and 56?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
8/1/26
Study Completion
8/1/27
Sponsor
EyePoint Pharmaceuticals, Inc.
Ticker
$EYPT
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
400
NCT
NCT06668064
Trial Description
This Phase 3 study tests EYP-1901 for wet age-related macular degeneration, measuring best-corrected vision change at about one year.